{"id":"topical-latanoprost-0-005","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Conjunctival hyperemia"},{"rate":"10-30","effect":"Iris pigmentation increase"},{"rate":"10-25","effect":"Eyelash growth (hypertrichosis)"},{"rate":"5-15","effect":"Eye irritation/discomfort"},{"rate":"5-10","effect":"Periocular skin pigmentation"}]},"_chembl":{"chemblId":"CHEMBL1051","moleculeType":"Small molecule","molecularWeight":"432.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Latanoprost acts as a selective agonist at the prostaglandin F (FP) receptor, primarily located on the ciliary muscle bundle and trabecular meshwork of the eye. By activating these receptors, it enhances drainage of aqueous humor through the unconventional uveoscleral pathway, reducing intraocular pressure. This mechanism makes it effective for treating glaucoma and ocular hypertension.","oneSentence":"Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:12.050Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07354516","phase":"PHASE2, PHASE3","title":"Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"Qlaris Bio, Inc.","startDate":"2026-03-18","conditions":"OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension","enrollment":36},{"nctId":"NCT04500574","phase":"PHASE1","title":"Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension","status":"TERMINATED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2024-04-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":1},{"nctId":"NCT06960629","phase":"","title":"The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)","status":"ENROLLING_BY_INVITATION","sponsor":"University Hospital Dubrava","startDate":"2025-04-01","conditions":"Pseudophakic Bullous Keratopathy, Glaucoma","enrollment":50},{"nctId":"NCT06407973","phase":"PHASE4","title":"A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma","status":"TERMINATED","sponsor":"Sight Sciences, Inc.","startDate":"2024-08-21","conditions":"Primary Open Angle Glaucoma","enrollment":2},{"nctId":"NCT01704989","phase":"PHASE4","title":"The Laser in Pseudoexfoliation (LIP) Study","status":"WITHDRAWN","sponsor":"Nova Scotia Health Authority","startDate":"2012-06","conditions":"Glaucoma","enrollment":""},{"nctId":"NCT05513924","phase":"PHASE2, PHASE3","title":"Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.","status":"COMPLETED","sponsor":"South Valley University","startDate":"2022-03-15","conditions":"Vitiligo","enrollment":40},{"nctId":"NCT03284853","phase":"PHASE3","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-09-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":436},{"nctId":"NCT03648229","phase":"PHASE4","title":"African Glaucoma Laser Trial","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2019-09-01","conditions":"Open-angle Glaucoma","enrollment":""},{"nctId":"NCT03216902","phase":"PHASE2","title":"A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2017-07-25","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":241},{"nctId":"NCT04234932","phase":"EARLY_PHASE1","title":"Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation","status":"UNKNOWN","sponsor":"University of the Incarnate Word","startDate":"2020-01-06","conditions":"Glaucoma, Open-Angle","enrollment":10},{"nctId":"NCT02017327","phase":"PHASE4","title":"Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2013-12","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":379},{"nctId":"NCT03293992","phase":"PHASE1","title":"A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-10","conditions":"Glaucoma, Open-angle, Ocular Hypertension","enrollment":27},{"nctId":"NCT04178863","phase":"PHASE4","title":"CATS Tonometer IOP Reduction Latanoprost Verses Timolol","status":"UNKNOWN","sponsor":"Intuor Technologies, Inc.","startDate":"2018-07-01","conditions":"Glaucoma; Drugs","enrollment":72},{"nctId":"NCT03611348","phase":"PHASE2, PHASE3","title":"Microneedling and Latanoprost in Acrofacial Vitiligo","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2018-09-01","conditions":"Vitiligo","enrollment":70},{"nctId":"NCT00712400","phase":"NA","title":"Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2005-06","conditions":"Ocular Physiology, Intraocular Pressure, Regional Blood Flow","enrollment":24},{"nctId":"NCT01927406","phase":"PHASE4","title":"The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2014-06","conditions":"Thyroid Eye Disease, Ocular Hypertension, Glaucoma","enrollment":""},{"nctId":"NCT02622334","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-12-29","conditions":"Glaucoma","enrollment":45},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT02350023","phase":"PHASE4","title":"Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2014-09","conditions":"Alopecia Areata","enrollment":50},{"nctId":"NCT01369771","phase":"PHASE4","title":"The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma","status":"COMPLETED","sponsor":"FinnMedi Oy","startDate":"2010-08","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":30},{"nctId":"NCT01896180","phase":"PHASE2","title":"Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost","status":"COMPLETED","sponsor":"Alleanza Pharmaceuticals, Inc.","startDate":"2013-07","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension, Elevated Intraocular Pressure","enrollment":63},{"nctId":"NCT01639807","phase":"NA","title":"Clinical Evaluation of Efficacy of SLT to Topical Medication in Lowering IOP","status":"UNKNOWN","sponsor":"Aurolab","startDate":"2011-10","conditions":"Glaucoma","enrollment":600},{"nctId":"NCT00868894","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2009-03","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":49},{"nctId":"NCT00650338","phase":"PHASE2","title":"Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2008-03","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":165},{"nctId":"NCT00799682","phase":"PHASE4","title":"Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®","status":"COMPLETED","sponsor":"Ophthalmic Consultants of Long Island","startDate":"2008-10","conditions":"Dry Eye Disease","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Topical latanoprost 0.005%","genericName":"Topical latanoprost 0.005%","companyName":"Post Graduate Institute of Medical Education and Research, Chandigarh","companyId":"post-graduate-institute-of-medical-education-and-research-chandigarh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}